🔗 Share this article WHO Raises Concern Over Acute Lack of Weight-Loss Medications Under a tenth of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it publishes its inaugural recommendations on the medications. Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable availability to this class of drugs. According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "The new guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to widespread availability to the injections that can help people shift considerable weight, explains the agency. Skinny Jab Supply Crisis Even in the current most favorable case, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of those who need them, according to the WHO. The guideline urges governments and firms to expand availability, by strategies like patent sharing. A patent on the active ingredient – the core component of a leading brand – is due to expire in multiple countries in 2026. How Weight-Loss Injections Work These medications replicate a body's own hormone to slow digestion, curb appetite and increase satiety so individuals consume fewer calories. Individuals typically start to lose weight in the initial weeks of commencing the once-weekly jabs. Evidence suggests people may put most of the weight back on a year later of stopping the treatment, because their usual appetite come back. To be above a healthy weight elevates your chance for contracting health problems, including diabetes, heart disease, brain attack, and some cancers. Obesity affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the WHO.
Under a tenth of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it publishes its inaugural recommendations on the medications. Given in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable availability to this class of drugs. According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "The new guidance acknowledges that excess weight is a chronic disease that can be addressed with thorough and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to widespread availability to the injections that can help people shift considerable weight, explains the agency. Skinny Jab Supply Crisis Even in the current most favorable case, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of those who need them, according to the WHO. The guideline urges governments and firms to expand availability, by strategies like patent sharing. A patent on the active ingredient – the core component of a leading brand – is due to expire in multiple countries in 2026. How Weight-Loss Injections Work These medications replicate a body's own hormone to slow digestion, curb appetite and increase satiety so individuals consume fewer calories. Individuals typically start to lose weight in the initial weeks of commencing the once-weekly jabs. Evidence suggests people may put most of the weight back on a year later of stopping the treatment, because their usual appetite come back. To be above a healthy weight elevates your chance for contracting health problems, including diabetes, heart disease, brain attack, and some cancers. Obesity affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the WHO.